Peer-reviewed veterinary case report
Using somatostatin drugs to find and treat gastrinoma in a dog
By Altschul, M et al.·Published in The Journal of small animal practice·1997·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of somatostatin analogues for the detection and treatment of gastrinoma in a dog.
- Species:
- dog
Plain-English summary
A 9-year-old male dog was diagnosed with gastrinoma, a type of tumor that causes excessive gastrin production, leading to digestive issues. After using a special imaging technique, the vet found tumors in the pancreas and liver. The dog was treated with a medication called octreotide, which helped lower gastrin levels, along with other medications to manage symptoms. Thanks to this combination treatment, the dog lived for an additional 14 months with a good quality of life.
People also search for: dog gastrinoma treatment · octreotide for dogs · dog pancreas tumor symptoms
Abstract
Gastrinomas in dogs are difficult to diagnose, localise and treat. In humans, somatostatin analogues have improved localisation and treatment of gastrinomas. The somatostatin analogues pentetreotide and octreotide were evaluated for the detection and treatment of gastrinoma in a dog. 111indium-pentetreotide scintigraphy revealed multiple areas of activity in the patient's mid-ventral abdomen which were consistent with masses in the pancreas and liver at laparotomy. Immunohistochemistry, electron microscopy and binding of 125I-[Tyr3]-octreotide in vitro confirmed the lesion as a gastrinoma which expressed somatostatin receptors. Octreotide at doses of 2, 4 and 8 micrograms/kg caused transient decreases in circulating gastrin. Plasma somatostatin peaked at one hour after octreotide and was still detectable at four and six hours after administration of octreotide. Combination therapy with famotidine, omeprazole, sucralfate and increasing doses of octreotide allowed patient survival for 14 months.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/9239629/